98%
921
2 minutes
20
Background: Mammography is the cornerstone of breast cancer screening. Its diagnostic performance, however, is influenced by population demographics such as age and breast density.
Purpose: The aim of this study was to establish contemporary performance benchmarks for mammography screening in Bahrain's primary health-care centres (PHCs) and to identify areas for quality improvement.
Methods: A cross-sectional retrospective analysis was performed on mammograms from asymptomatic women aged ≥40 years who were screened in 2020 at primary health care centres. Screening outcomes were cross-referenced with subsequent breast cancer diagnoses recorded in the Bahrain Cancer Registry (2021-2022). Mammographic findings were categorised using the Breast Imaging Reporting and Data System (BI-RADS), and performance metrics including the cancer detection rate (CDR), sensitivity, and specificity were calculated.
Results: A total of 2196 screening mammograms were included, with a mean patient age of 56.1 years. The cancer detection rate was 12.3 per 1000 screens, and the recall rate was 30.6%. Sensitivity and specificity were 69.2% and 71.2%, respectively, and the interval cancer rate was 5.4 per 1000. The most common breast density category was "scattered fibroglandular" (61.8%). Recall rates were significantly associated with breast density (p < 0.001). Among the 39 patients diagnosed with breast cancer, invasive ductal carcinoma was the most prevalent subtype (71.8%).
Conclusion: The findings highlight the moderate utility of mammography screening in Bahrain, characterised by a relatively high recall rate and a need to optimise reporting standards and recall criteria. Tailored strategies such as supplemental imaging for women with dense or high-risk breasts, strict adherence to BI-RADS guidelines, and implementing double reading or single reading with computer-aided detection could improve screening outcomes. These results establish important regional performance benchmarks and can inform policies to enhance breast cancer detection and management in the Arabian Gulf region.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12372806 | PMC |
http://dx.doi.org/10.2147/IJWH.S535787 | DOI Listing |
BMC Cancer
September 2025
Klinik für Innere Medizin II, Universitätsklinikum Jena, Am Klinikum 1, Jena, 07747, Germany.
Acta Pharmacol Sin
September 2025
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Chemotherapeutic resistance is a significant issue in the treatment of breast cancer, which is related to pyroptosis inhibition. Increasing evidence suggests that long non-coding RNAs (lncRNAs) contribute to tumorigenesis and drug resistance. In this study we investigated the role of the lncRNA STMN1P2 in doxorubicin resistance in breast cancer, as well as its correlation with pyroptosis inhibition.
View Article and Find Full Text PDFJ Hum Genet
September 2025
Division of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Comprehensive genomic profiling (CGP) expands treatment options for solid tumor patients and identifies hereditary cancers. However, in Japan, confirmatory tests have been conducted in only 31.6% of patients with presumed germline pathogenic variants (GPVs) detected through tumor-only testing.
View Article and Find Full Text PDFCardiovasc Intervent Radiol
September 2025
The Department of Radiology, Wakayama Medical University, Wakayama, Japan.
Purpose: Recent advancements in medical technologies have made trans-arterial treatment of breast cancer feasible. Consequently, understanding the vascular anatomies of breast cancers and axillary lymph node metastases has become indispensable for sophisticated treatments. The aim of this study was to determine the vascular anatomy of the breast, which is crucial for trans-arterial chemoembolization in patients with breast cancer.
View Article and Find Full Text PDFNat Commun
September 2025
Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, 90033, California, USA.